All In Biotech

Drug Trial Radar · NCT05209308

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

A Phase 2 Single-Arm, Open-Label Study to Assess the Safety and Efficacy of Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia - The CORAL Study

Last checked: Nov 19, 2026Latest source record: Mar 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Nov 22, 2022

Primary completion

Mar 15, 2023

Study completion Mar 15, 2023

Sponsor

Lead sponsor
MEI Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Kyowa Kirin, Inc.
First posted
Jan 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 study of Zandelisib with Venetoclax (VEN) and Rituximab (R) in subjects with Relapsed/Refractory CLL.

Conditions

  • CLL

Interventions

  • ZandelisibDrug

    Zandelisib taken orally for 7 days of each 28 day cycle

  • RituximabDrug

    Rituximab IV for 6 cycles

  • VenetoclaxDrug

    Orally - Ramp up weeks 1-5

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the uMRD rate in PB and BM by flow cytometryTime frame: 2 year

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Stony Brook University

    Stony Brook, New York

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Medical Oncology Associates, PS (dba Summit Cancer Centers)

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.